Judith Hsia 202-741-2321. Hormone Therapy Trial: Coronary Heart Disease & Fractures. Adverse effect for Breast Cancer? Calcium/Vitamin.

Slides:



Advertisements
Similar presentations
SABCS 2011 BOLERO-2 Updated Results
Advertisements

Women's Health Initiative
Your Institution Here Your Institution Here Cardiovascular Disease in Women: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa
Cardiovascular Disease in Women Module VI: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators (SERMs)
Calcium/Vitamin D-related CV Events Based on Poster 1163 “Risk of Cardiovascular Events with Calcium/Vitamin D – a Re-Analysis of the Women’s Health Initiative”
Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.
Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy The Women’s Health Initiative Randomized Controlled Trial JAMA 2004;291:
CaD TrialObservational Study All participantsNo Personal Supplements a Non-users ofCalcium +CalciumVitamin D PlaceboCaDPlaceboCaDSupplementsVitamin DOnly.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Women’s Health Initiative (WHI) Clinical Trials (CT) Observational Study (OS) Diet Modification (DM) Hormone Replacement Therapy (HRT) Calcium +Vitamin.
1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.
Linda Snetselaar, PhD, RD Professor Interim Chair of the Department of Community and Behavioral Health College of Public Health University of Iowa.
A Randomized Trial of a Multivitamin in the Prevention of Cardiovascular Disease in Men: The Physicians’ Health Study II HD Sesso, WC Christen, V Bubes,
Hormone Replacement Therapy 5/11/07 5/11/07Tanu. History of HRT Approximately 100years of research and 80 years of clinical practice Ovarian extracts.
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
1 Study of Tamoxifen and Raloxifene STAR Larry Wickerham, MD NSABP STAR Project Officer.
Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.
Journal Club Hallie Lee PharmD Candidate 2013 Mercer University COPHS PHA 618 Geriatrics-Continuous Care Multivitamins in the Prevention of Cardiovascular.
Slide Source: Lipids Online Slide Library Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608.
Women’s Health Initiative: HRT Trial Baseline Data and Update on Follow-up Marcia L. Stefanick, Ph.D. Associate Professor of Medicine and of Obstetrics.
Beyond Standard Adjuvant Therapy for Colon Cancer: Role of Nonstandard Interventions Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
The Women’s Health Initiative Hormone Trials The Estrogen Only (women with a hysterectomy at baseline) and the Estrogen + Progestin (women with a uterus)
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
National Heart, Lung, and Blood Institute Women’s Health Initiative Branch Jacques Rossouw, MD Chief, WHI Branch Program for Prevention and Population.
FDA Presentation ODAC Meeting July NDA Applicant: Eli Lilly Evista ® (Raloxifene Hydrochloride)
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
WHI CT Sample Size, Outcomes, Follow-up Women, aged Total CT = 68,133 Diet Modification (DM) Trial Primary Outcomes: Breast & Colorectal Cancer Secondary.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.
MENAPOUSE. Natural Surgical premature RETROSPECTIVE Cessation of menstruation for 12 months In the absence of other physiological or psychological.
HERS, ERA and WHI: Recent trials in hormone replacement therapy Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.
STAR. 2 NSABP P-1 Trial Results: Age > 50 Category TamoxifenPlacebo ARD RR(95% CI) n 4010 IR n 4008 IR Breast Cancer Invasive Invasive Non-invasive Non-invasive
4S: Scandinavian Simvastatin Survival Study
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Estrogen Plus Progestin and Breast Cancer Incidence.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During.
Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.
Date of download: 6/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Homocysteine-Lowering With Folic Acid.
Date of download: 6/18/2016 From: Treatment of Anemia in Patients With Heart Disease: A Systematic Review Ann Intern Med. 2013;159(11): doi: /
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Genetic Inhibition of CETP, Ischemic Vascular Disease.
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
The Rise and Fall of Hormone Replacement Therapy
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Diabetes in Postmenopausal Women The Women’s Health Initiative
A Low-Fat Dietary Pattern Slows Progression of Diabetes: Results from the WHI Dietary Modification Trial Barbara V Howard, PhD Sr Scientist , MedStar.
The Future of Molecular-Targeted Cancer Chemoprevention
سرطان الثدي Breast Cancer
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
4D trial: Primary end point
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
(p for noninferiority < 0.001)
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Associations between type of MI and incident HF
FIELD: Primary outcome
Estrogen and progestogen therapy in postmenopausal women
Presentation transcript:

Judith Hsia

Hormone Therapy Trial: Coronary Heart Disease & Fractures. Adverse effect for Breast Cancer? Calcium/Vitamin D Trial: Fractures & Colorectal Cancer Dietary Modification Trial: Breast & Colorectal Cancers & Coronary Heart Disease 93,676 Observational Study 48,835 36,282 3 Controlled Trials 1 Observational Study 27, ,808 women total Women’s Health Initiative

CV risk with PreHTN NormalPrehypertensionHypertension N (Ann %) HR N (Ann %)HR (95% CI) N (Ann %) HR (95% CI) CVdeath 83 (0.07) (0.12) 1.58 (1.12, 2.21) 510 (0.32) 3.02 (2.18, 4.18) MI 177 (0.14) (0.24) 1.76 (1.40, 2.22) 770 (0.48) 2.86 (2.28, 3.59) Stroke 137 (0.11) (0.22) 1.93 (1.49, 2.50) 778 (0.49) 3.62 (2.82, 4.66) CHF 137 (0.11) (0.19) 1.36 (1.05, 1.77) 848 (0.53) 2.78 (2.17, 3.57) Any CV event 442 (0.35) (0.66) 1.66 (1.44, 1.92) 2253 (1.41) 2.89 (2.52, 3.32) Stratified by age and trial participation; adj for age, BMI, DM, high chol and smoking

Other studies “Pilot study to identify novel biomarkers of myocardial necrosis” “Pilot study to identify novel biomarkers of myocardial necrosis” American Red Cross; David Hammond, PI American Red Cross; David Hammond, PI Selenium and Vitamin E Chemoprevention Trial (SELECT) Selenium and Vitamin E Chemoprevention Trial (SELECT) NCI via subcontract with SWOG NCI via subcontract with SWOG Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer National Cancer Institute of Cancer National Cancer Institute of Cancer